RE:Re: The PathNot very often but sometimes freak circumstance offers a rare opportunity. The combination of CZO's major client undergoing reoganization which had never happened before, and the worst biotech market in history that has left many biotechs like AEZS trading below cash, plus AEZS being before trial results, approval and an expected licensing deal with Gilles on the inside appears to have created a rare opportunity. CZO has never released data for the avenanthramide pill which will have safety/tolerability, and preliinary efficacy data this year. PGX is also only at pilot scale currently with 5X and 10X scale-up to the point of decision for mass industrialization expected this year. Gilles knows the deals they've been discussing. We are at the bottom of the mountain and just before key data and potential deals. Gilles, in a sense, already appears at the top of the mountain with Ronnie Miller, and Bloom Burton by their side. They are 'thrilled'. The Chair of AEZS is 'compelled' with Raymond James and Gilles by her side in an apparent relationship of trust. AEZS and CZO are under the radar. Gilles wants CZO's pipeline on NASDAQ as events are told. The full plan and details of the merger and priorities are yet to be released. The daisy chain of events in motion will tell the story.
fossi_2002 wrote: And all for c$13 million. - what nonsense "The combination is attractive for shareholders of both companies, as it is expected to create a long-term sustainable business..." news release
The path to a long-term sustainable business is key.
The merger provides capital and internal capabilities from AEZS to "fully support" CZO's near-term revenue generatng development programs. Gilles Gagnon, Chief Executive Officer of Ceapro: “The transaction provides us with the additional capital and internal capabilities to fully support near-term revenue generating cosmeceutical and nutraceutical product development programs..." news release With financing and internal capabilities in place you can see why Ronnie Miller is "thrilled", Gilles is 'excited' and the Chair of AEZS is 'compelled'. Gilles is on the insideof both CZO and AEZS and knows the deals, etc., being worked on. Gilles wants CZO's pipeline on NASDAQ now for a reason. Given H.C. Wainwright's US$15 target and that it is a merger of equals the target valuation of this deal is arguably C$200 million or ~$1.25 per current CZO share.
The path,
the daisy chain of events that will define this merger... AEZS's diagnostic test clinical trial results for children
Launch of powder formulations of CZO's two active ingredients(beta glucan, avenanthramide)
CZO's main client returns
AEZS's diagnostic continuing roll-out for adults
FDA approval for the test for children
Licensing deal for the diagnostic test for North America
Commissioning of 5X PGX scale-up
Commissioning of 10X scale-up to decision point for mass industrialization of PGX
PGX licensing deal
Immune booster plant
Phase I avenanthramide clinical trial results
Wound healing results
Wound healing partnership
Fibrosis clinical trial 'go'/'no go' decision and regulatory filing
Phase IIa avenanthramide clinical trial results
Avenanthramide pill partnership
AIM Biologicals 'go'/'no go' clinical trial decision
